Previous 10 | Next 10 |
Biopharma industry analysts have been expecting 2022 to be a heady year for big-pharma acquisitions or partnerships with promising medical upstarts following a time period that has left the biggest companies flush with cash Among promising device and drug developers, Odyssey Health Inc....
No adverse reactions were reported in any of the healthy subjects enrolled in the Cohort II Phase 1 clinical trial of PRV-002 Company in talks with military training sites for Phase 2 and 3 clinical trials on concussed patients The CDC estimates that approximately 1.6 to 3.8 mil...
Odyssey Health is a medical company focused on developing medical products for conditions with unmet needs, one of which is concussion Currently, concussions do not have an FDA-approved treatment Soldiers form a significant population of people who frequently experience multiple concu...
Odyssey Health (OTC: ODYY) , f/k/a Odyssey Group International Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from cohort II of its phase I clinical trial. According to the update, the trial involves administering PRV-002...
Las Vegas, NV, June 29, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from Cohort II of their Phase I clinical trial. Ody...
Odyssey Health is focused on developing life-saving medical products and pharmaceutical assets that offer a technological and clinical advantage The company is developing the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device Its drug-device com...
Odyssey Health (OTC: ODYY) understands the severity of concussions among service members as well as the existing gaps in treatment. The Center for Disease Control (“CDC”) reports that over 430,000 military service members were diagnosed with traumatic brain injury (“TB...
Odyssey Group International Inc. is a Nevada based medical company developing a variety of drug and technology assets to treat unmet clinical needs Odyssey CEO Michael Redmond recently appeared on Bloomberg TV’s The RedChip Money Report(R) to discuss the development pipeline for ...
Odyssey Health (OTC: ODYY) recently completed a safety evaluation of cohort I of its phase I clinical trial administering PRV-002, the company’s novel drug treatment for concussion. “Findings from the cohort, which included eight healthy human volunteers that received a singl...
Odyssey is a medical company developing PRV-002, a novel compound for the treatment of concussion Between 75-83% of all the cases of traumatic brain injury (“TBI”) among U.S. service members have been classified as mild (“mTBI”), commonly termed “concu...
News, Short Squeeze, Breakout and More Instantly...
Odyssey Group International Inc Company Name:
ODYY Stock Symbol:
OTCMKTS Market:
Odyssey Group International Inc Website:
LAS VEGAS, NV / ACCESSWIRE / March 27, 2024 / Odyssey Health, Inc. (OTCQB:ODYY) , formerly Odyssey Group International, Inc., (the "Company") a company focused on developing unique, life-enhancing medical products, recently filed its quarterly report for the quarter ended January 31, 2024. The ...
LAS VEGAS, NV / ACCESSWIRE / January 2, 2024 / Odyssey Health, Inc. (OTCQB:ODYY) ("Odyssey" or the "Company") today announces the closing of the definitive Asset Purchase Agreement, that was entered into on October 4, 2023, with Oragenics, Inc., (OGEN:NYSE American) under which Oragenics acquire...
LAS VEGAS, NV / ACCESSWIRE / December 12, 2023 / Odyssey Health, Inc. ( OTCOB:ODYY ), a company focused on developing unique, life-enhancing medical products including a drug treatment intended to treat concussion, announces that it has received stockholder approval for the sale of its neurologi...